Adn-388 May 2026

: It is engineered to minimize the recruitment of -arrestin. In traditional drugs,

is a potent investigational weight-loss drug currently in Phase III clinical development. Developed by Roche and its subsidiary Genentech, this once-weekly subcutaneous injection belongs to the "incretin mimetic" class, similar to popular medications like Wegovy and Zepbound. Core Mechanism: How CT-388 Works ADN-388

: Like tirzepatide (Zepbound), it activates both the Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP) receptors to suppress appetite and enhance insulin secretion. : It is engineered to minimize the recruitment of -arrestin

-arrestin causes receptors to "internalize" or become desensitized over time. By avoiding this, CT-388 aims for prolonged pharmacological activity and potentially more durable weight loss. ADN-388